Renalytix - SG&A Expenses 2020-2024 | RNLXY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Renalytix - sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Renalytix - sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Veeva Systems (VEEV)	$46.9B
Hims & Hers Health (HIMS)	$13.5B
Doximity (DOCS)	$11.2B
Tempus AI (TEM)	$10.1B
IRhythm Technologies (IRTC)	$4.4B
Inspire Medical Systems (INSP)	$3.8B
Hinge Health (HNGE)	$3.4B
Privia Health (PRVA)	$2.4B
10x Genomics (TXG)	$1.7B
Phreesia (PHR)	$1.6B
Enovis (ENOV)	$1.6B
Schrodinger (SDGR)	$1.6B
Azenta (AZTA)	$1.6B
Clover Health Investments (CLOV)	$1.5B
Omnicell (OMCL)	$1.4B
Evolent Health (EVH)	$1.1B
Claritev (CTEV)	$635M
Fulgent Genetics (FLGT)	$535M
Standard BioTools (LAB)	$528M
Veradigm (MDRX)	$503M
Butterfly Network (BFLY)	$453M
Talkspace (TALK)	$420M
TruBridge (TBRG)	$328M
Outset Medical (OM)	$311M
Health Catalyst (HCAT)	$273M
Nyxoah SA (NYXH)	$255M
SOPHiA GENETICS SA (SOPH)	$218M
CapsoVision (CV)	$210M
Zepp Health (ZEPP)	$182M
KORU Medical Systems (KRMD)	$161M